SPOTLIGHT ... Avandia cleared FDA by one vote
Behind closed doors, the FDA's safety board barely backed GlaxoSmithKline's Avandia last month, voting 8-to-7 to keep the drug on the market with tougher warnings of heart risks rather than pull it completely. Report